Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Safety of Aliskiren/Amlodipine in Essential Hypertension
NCT00402103Phase 3Completed
- Sponsor
- Novartis
- Start
- Nov 2006
- Primary completion
- Apr 2008
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 3, open-label trial of aliskiren in hypertension (HTN) (2 arms), sponsored by Novartis. Primary endpoint: Overall Percentage of Patients With Adverse Events at 52 weeks. Started Nov 2006; status: completed.
02
Drugs
aliskiren
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT00402103.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00402103.